SCHEMBL8103707

SCHEMBL8103707

O=[C]OC(C(=O)OC(=O)c1ccccc1)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
CYP3A4 P08684 1/20 0.45
KMT2A Q03164 2/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
LMNA P02545 3/20 0.41
F2 P00734 1/20 0.41
TDP1 Q9NUW8 3/20 0.40
TSHR P16473 2/20 0.40
TP53 P04637 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
GAA P10253 1/20 0.39
SLC6A3 Q01959 2/20 0.39
MAPK1 P28482 1/20 0.39
HIF1A Q16665 1/20 0.39
SLC6A2 P23975 1/20 0.39
ESR1 P03372 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5157376 0.80 ALDH1A1 (0.64) ALDH1A1CYP3A4KMT2APOLBMAPT
SCHEMBL712324 0.78 KMT2A (0.56) ALDH1A1CYP3A4KMT2AMEN1LMNA
SCHEMBL710572 0.77 CYP2D6 (0.46) ALDH1A1CYP3A4KMT2ALMNATDP1
SCHEMBL8886285 0.77 L3MBTL1 (0.50) ALDH1A1CYP3A4KMT2ALMNATDP1
SCHEMBL1371273 0.75 MMP8 (0.50) ALDH1A1CYP3A4KMT2AMAPTMEN1
SCHEMBL1680117 0.74 ALDH1A1 (0.41) ALDH1A1CYP3A4KMT2APOLBMAPT
SCHEMBL212215 0.74 ALDH1A1 (0.51) ALDH1A1KMT2ALMNATDP1L3MBTL1
SCHEMBL9068581 0.74 ALDH1A1 (0.51) ALDH1A1CYP3A4KMT2ALMNATSHR
SCHEMBL28420265 0.74 LMNA (0.57) ALDH1A1KMT2ANPC1RAB9ALMNA
SCHEMBL9793557 0.73 KMT2A (0.46) ALDH1A1CYP3A4KMT2AMEN1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9150511-B2 Process for preparing saxagliptin and its novel intermediates useful in the synthesis thereof APICORE US LLC (US) 2015-10-06 US disclosed
US-20140235870-A1 PROCESS FOR PREPARING SAXAGLIPTIN AND ITS NOVEL INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF APICORE, LLC (US) 2014-08-21 US disclosed
WO-2012162507-A1 PROCESS FOR PREPARING SAXAGLIPTIN AND ITS NOVEL INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF APICORE, LLC (US) 2012-11-29 WO disclosed
US-6121442-A 1,2-dialkinylated compounds UNIVERSITY OF HEILDELBERG (DE) 2000-09-19 US disclosed
WO-1998000386-A1 1,2-DIALKINYLATED COMPOUNDS Universität Heidelberg (DE) 1998-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140235870-A1 PROCESS FOR PREPARING SAXAGLIPTIN AND ITS NOVEL INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF DPP4, DPP3, DPP8 ALDH1A1 1533/4885CYP3A4 38/4885KMT2A 3906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.